These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 2916524)

  • 1. Concomitant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine.
    Cesana M; Mandelli C; Tiribelli C; Bianchi PA; Conte D
    Am J Gastroenterol; 1989 Feb; 84(2):150-2. PubMed ID: 2916524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis.
    Kellner H; Zoller WG
    Z Gastroenterol; 1992 Nov; 30(11):779-83. PubMed ID: 1471384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 3 hemochromatosis and beta-thalassemia trait.
    Riva A; Mariani R; Bovo G; Pelucchi S; Arosio C; Salvioni A; Vergani A; Piperno A
    Eur J Haematol; 2004 May; 72(5):370-4. PubMed ID: 15059075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Iron overload in a beta thalassemia heterozygote of the intermediate type in a subject of Alsation origin. Results of iron chelation treatment].
    North ML; Lang JM; Bergerat JP; Giron C; Oberling F; Mayer S
    Nouv Rev Fr Hematol (1978); 1984; 26(5):317-21. PubMed ID: 6334273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition and treatment of iron overload.
    Brown EB
    Adv Intern Med; 1980; 26():159-86. PubMed ID: 7013439
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of erythrocytapheresis in idiopathic hemochromatosis. Report of 14 cases.
    Conte D; Mandelli C; Cesana M; Ferrini R; Marconi M; Bianchi A
    Int J Artif Organs; 1989 Jan; 12(1):59-62. PubMed ID: 2925263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New diagnostic and therapeutic possibilities in manifest idiopathic hemochromatosis.
    Volkholz HJ; Sailer D; Rödl W
    Hepatogastroenterology; 1984 Dec; 31(6):289-94. PubMed ID: 6519641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 10. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S; Philippidis P; Drossos C; Economidis J
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathogenesis and management of iron overload in thalassemia.
    Hershko C
    Haematologica; 1975 Jun; 60(2):241-8. PubMed ID: 808456
    [No Abstract]   [Full Text] [Related]  

  • 16. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
    Ambrus CM; Stadler I; Toumbis CA; Stadler A; Anthone S; Anthone R; DeAlarcon P; Deshpande G; Conway J; Vladutiu AO; Ambrus JL
    J Med; 1999; 30(3-4):211-24. PubMed ID: 17312675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy.
    Muncunill J; Vaquer P; Galmés A; Obrador A; Parera M; Bargay J; Besalduch J
    J Clin Apher; 2002; 17(2):88-92. PubMed ID: 12210712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Idiopathic hemochromatosis--diagnosis and therapy].
    Schmidt U; Preu E; Tuschy U; Senf L; Herre K
    Z Gesamte Inn Med; 1984 Apr; 39(8):152-60. PubMed ID: 6730591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of iron overload.
    Cohen A; Witzleben C; Schwartz E
    Semin Liver Dis; 1984 Aug; 4(3):228-38. PubMed ID: 6091277
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.